Steve Aselage, Director at BIOCRYST PHARMACEUTICALS INC (BCRX), bought 2,500 shares at $6.40 ($16K) on 2024-05-24, disclosed to the SEC on 2024-05-29.
Open-market purchase of $16k BCRX by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade B.
Something here stands out, but not much.
| Filing → |
| ACER | BUY | 2021-12-13 | $21K | — | Filing → |
| TVTX | SELL | 2021-11-18 | $935K | — | Filing → |
| TVTX | SELL | 2021-11-09 | $262K | — | Filing → |